Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
基本信息
- 批准号:9080884
- 负责人:
- 金额:$ 39.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-01 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AllelesAttentionBiological ModelsBiologyCancer BiologyCancer EtiologyCessation of lifeClinicalClinical TrialsColorectal CancerDataDependencyDiseaseDissectionDrug IndustryEvolutionFutureGeneticGenetically Engineered MouseGoalsGrowthGuanosine Triphosphate PhosphohydrolasesHumanIndividualInjection of therapeutic agentKRAS2 geneLeftMEKsMaintenanceMalignant neoplasm of pancreasMalignant neoplasm of prostateMediatingMediator of activation proteinMemorial Sloan-Kettering Cancer CenterMolecularMusMutationOncogenicOrganoidsOutcomePI3K/AKTPathway interactionsPatientsPhenotypePhospholipidsPhosphotransferasesProductionRALA geneRefractoryResearch Project GrantsRoleSignal PathwaySignal TransductionSystemTechniquesTechnologyTestingTherapeuticTimeTumor-DerivedUnited Statesbaseblastocystcohortdesigneffective therapyembryonic stem cellin vitro Modelinhibitor/antagonistinnovationknock-downmalignant breast neoplasmmouse modelmutantnovelnovel therapeuticspancreatic neoplasmpublic health relevancetherapeutic targettumor
项目摘要
DESCRIPTION (provided by applicant): This research project seeks to comprehensively determine signaling pathway dependencies downstream from oncogenic KRAS in mouse and human pancreatic cancer. While KRAS itself has so far proven refractory to direct pharmacologic targeting, an array of potentially druggable signaling effectors convey signaling downstream from mutant KRAS. These effectors include: 1) the RAF/MEK/ERK kinase cascade; 2) Phospholipid signaling mediated by PLC/PKC and PI3K/AKT; and 3) GTPase signaling mediating by RALA/B and RAC1. A small subset of these downstream effectors have been interrogated for requisite roles in the initiation of pancreatic cancer precursors. However, none have been genetically evaluated with respect to a requisite role in the maintenance of established pancreatic cancer, leaving substantial gaps in our ability to rationally plan therapeutic targeting of these pathways. We therefore propose to genetically dissect these potentially druggable downstream mediators in both mouse and human model systems. The central hypotheses of this project are: First, that the individual components of the composite phenotype induced by mutant Kras will be dependent upon different downstream signaling mediators; second, that combined genetic and pharmacologic targeting of downstream mediators will reveal novel therapeutic vulnerabilities; and third, that different mutant Kras alleles may be differentially sensitive to therapeutic disruption of individual signaling pathways.
To test these hypothesis, we propose the following Specific Aims: 1) To create new GEMM ESC-based murine models allowing for the timed inactivation of Raf1, Pik3ca, PLCε, RalA/B and Rac1 in established pancreatic tumors; 2) To combine genetic and pharmacologic inhibition of different downstream KRAS mediators to identify new therapeutic synergies and vulnerabilities using a human pancreatic cancer 3D organoid culture system; and 3) To create and compare new ESC-based genetically engineered mouse models involving Kras G12R and Q61H. The project leverages highly innovative "Speedy" GEMM ESC mouse technology, including a new dedicated blastocyst injection facility, as well as novel techniques for 3D organoid culture of patient-derived tumor organoids. Together, these studies will for the first tim provide a comprehensive analysis of downstream signaling dependencies in established Kras-driven pancreatic cancer. We anticipate that these studies will inform the design of future clinica trials in which these dependencies are exploited for therapeutic gain.
描述(申请人提供):该研究项目旨在全面确定小鼠和人类胰腺癌中致癌KRAS下游信号通路的依赖性。虽然KRAS本身迄今已被证明对直接药理学靶向是难治的,但一系列潜在的可药物化信号传导效应物从突变KRAS向下游传递信号传导。这些效应器包括:1)RAF/MEK/ERK激酶级联; 2)由PLC/PKC和PI 3 K/AKT介导的磷脂信号传导;和3)由RALA/B和RAC 1介导的GTT信号传导。这些下游效应子的一小部分已经被询问在胰腺癌前体的起始中的必要作用。然而,没有一个基因在维持已建立的胰腺癌中的必要作用方面进行了遗传评估,这使得我们在合理规划这些途径的治疗靶向方面存在很大的差距。因此,我们建议在小鼠和人类模型系统中对这些潜在的可药用下游介质进行遗传解剖。该项目的中心假设是:第一,由突变Kras诱导的复合表型的单个组分将依赖于不同的下游信号传导介质;第二,下游介质的组合遗传和药理学靶向将揭示新的治疗弱点;第三,不同的突变Kras等位基因可能对单个信号传导通路的治疗中断具有不同的敏感性。
为了验证这些假设,我们提出了以下具体目的:1)建立新的基于GEMM ESC的小鼠模型,允许在已建立的胰腺肿瘤中定时失活Raf 1、Pik 3ca、PLCε、RalA/B和Rac 1; 2)使用人胰腺癌3D类器官培养系统将不同下游KRAS介质的遗传和药理学抑制结合联合收割机以鉴定新的治疗协同作用和弱点; 3)建立并比较Kras G12 R和Q61 H基因工程小鼠模型。该项目利用高度创新的“快速”GEMM ESC小鼠技术,包括新的专用囊胚注射设施,以及用于患者源性肿瘤类器官的3D类器官培养的新技术。总之,这些研究将首次提供一个全面的分析下游信号依赖性在既定的Kras驱动的胰腺癌。我们预计这些研究将为未来临床试验的设计提供信息,在这些临床试验中,这些依赖性被用于治疗增益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven D Leach其他文献
Steven D Leach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven D Leach', 18)}}的其他基金
Developing ATAC-array as a novel epigenetic biomarker to guide personalized therapy in pancreatic cancer
开发 ATAC 阵列作为新型表观遗传生物标志物来指导胰腺癌的个性化治疗
- 批准号:
10512502 - 财政年份:2022
- 资助金额:
$ 39.21万 - 项目类别:
Administrative supplement for Early Drug Development Opportunity Program (EDDOP)
早期药物开发机会计划 (EDDOP) 的行政补充
- 批准号:
10677500 - 财政年份:2022
- 资助金额:
$ 39.21万 - 项目类别:
P30 Administrative Supplement to Cancer Center Support Grant to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network.
P30 癌症中心支持补助金的行政补充,旨在通过国家外展网络的社区健康教育者加强 NCI 支持的社区外展能力。
- 批准号:
10370916 - 财政年份:2021
- 资助金额:
$ 39.21万 - 项目类别:
Community-led Action Research in Oncology: Pandemic-appropriate Radiotherapy Innovations Evaluated for LMICs
社区主导的肿瘤学行动研究:针对中低收入国家评估适合流行病的放射治疗创新
- 批准号:
10380931 - 财政年份:2021
- 资助金额:
$ 39.21万 - 项目类别:
Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
- 批准号:
9476973 - 财政年份:2016
- 资助金额:
$ 39.21万 - 项目类别:
Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
- 批准号:
9922888 - 财政年份:2016
- 资助金额:
$ 39.21万 - 项目类别:
Functional Evaluation of Human Pancreatic Cancer Genes in a Zebrafish System
斑马鱼系统中人类胰腺癌基因的功能评估
- 批准号:
8464656 - 财政年份:2013
- 资助金额:
$ 39.21万 - 项目类别:
High resolution and single cell analyses of PanIN initiation and progression
PanIN 起始和进展的高分辨率单细胞分析
- 批准号:
8248212 - 财政年份:2011
- 资助金额:
$ 39.21万 - 项目类别:
High resolution and single cell analyses of PanIN initiation and progression
PanIN 起始和进展的高分辨率单细胞分析
- 批准号:
8095001 - 财政年份:2011
- 资助金额:
$ 39.21万 - 项目类别:
Confocal imaging resources for the JHU Zebrafish Center
JHU 斑马鱼中心的共焦成像资源
- 批准号:
7794133 - 财政年份:2010
- 资助金额:
$ 39.21万 - 项目类别:
相似国自然基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Development of social attention indicators of emerging technologies and science policies with network analysis and text mining
利用网络分析和文本挖掘开发新兴技术和科学政策的社会关注指标
- 批准号:
24K16438 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Improving Flexible Attention to Numerical and Spatial Magnitudes in Young Children
提高幼儿对数字和空间大小的灵活注意力
- 批准号:
2410889 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Continuing Grant
The Information-Attention Tradeoff: Toward an Understanding of the Fundamentals of Online Attention
信息与注意力的权衡:了解在线注意力的基本原理
- 批准号:
2343858 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Continuing Grant
Towards a cognitive process model of how attention and choice interact
建立注意力和选择如何相互作用的认知过程模型
- 批准号:
DP240102605 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Discovery Projects
The everyday learning opportunities of young children with attention and motor difficulties: From understanding constraints to reshaping intervention
注意力和运动困难幼儿的日常学习机会:从理解限制到重塑干预
- 批准号:
MR/X032922/1 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Fellowship
DDRIG in DRMS: Communicating risks in a sensational media environment-Using short video multimodal features to attract attention and reduce psychological reactance for persuasion
DRMS中的DDRIG:耸人听闻的媒体环境中沟通风险——利用短视频多模态特征吸引注意力,减少说服心理抵触
- 批准号:
2343506 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Standard Grant
Assessing the Influence of Reading Fiction on Multiple Tests of Attention
评估阅读小说对注意力多重测试的影响
- 批准号:
24K16033 - 财政年份:2024
- 资助金额:
$ 39.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Attention機構に基づく異種集合マッチング方式の分析と新方式の提案
基于注意力机制的异构集合匹配方法分析及新方法的提出
- 批准号:
23K11218 - 财政年份:2023
- 资助金额:
$ 39.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Effects of instruction using focus of attention on performance of chest compressions.
使用注意力集中的教学对胸外按压表现的影响。
- 批准号:
23K09887 - 财政年份:2023
- 资助金额:
$ 39.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Assessing the Influence of SDGs Formulation on Managers' Perceptions and CSR Activities: An Attention-based View
评估可持续发展目标制定对管理者认知和企业社会责任活动的影响:基于注意力的观点
- 批准号:
23K01515 - 财政年份:2023
- 资助金额:
$ 39.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)